Skip to main content
. 2021 May 25;26(10):2439–2444. doi: 10.1016/j.drudis.2021.05.012

Figure 1.

Figure 1

Distribution of compounds screened in the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) high-throughput screening (HTS) assays. The radar plot shows the number of compounds screened in each of the five assays that cover different stages in the SARS-CoV-2 life cycle, such as viral entry into host cells [angiotensin-converting enzyme 2 (ACE2) assay and Spike-ACE2 assay], viral replication [3-chymotrypsin-like protease (3CL) assay], in vitro infectivity [pseudotyped particle (PP) entry assay], and live virus infectivity [cytopathic effect (CPE) assay]. In the plot, each slice represents an assay, and the radius of the slice is proportional to the number of compounds screened in the assay.